TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38691823
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) and radiation therapy (RT)
Study: 32540986
Drug: DOSE HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOSE HPV intervention (7-session program including provider education, communication training, data feedback, and tailored systems change)
Study: 32540986
Drug: DOSE HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOSE HPV intervention
Study: 38982653
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose regimen
Study: 32086901
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray allergen blocker combined with azelastine hydrochloride nasal spray
Study: 32086901
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride nasal spray
Study: 33621541
Drug: ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ticagrelor plus aspirin (DAPT)
Study: 36327527
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) Q3W for four cycles with once-daily cabozantinib (40 mg), then nivolumab (240 mg) Q2W plus once-daily cabozantinib (40 mg)
Study: 35597972
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy/Motivational Interviewing (CBT/MI) intervention, administered in six sessions over 3 months.
Study: 32706937
Drug: Ribociclib 600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 600-mg tablet
Study: 32706937
Drug: Ribociclib 600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 600-mg capsule
Study: 32706937
Drug: Ribociclib intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib intravenous infusion 150 mg
Study: 32706937
Drug: Ribociclib oral
Normalized name: ribociclib Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib oral administration
Study: 32706937
Drug: Ribociclib 600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 600-mg tablet and capsule
Study: 33287685
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT), 4 sessions of 1 hour
Study: 34134828
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo augmented ERP
Study: 34529768
Drug: ATRA chemotherapy
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA chemotherapy
Study: 36152268
Drug: anti-HBc level
Normalized name: Aminosyn-HBC 7 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-HBc level <325 IU/ml
Study: 36152268
Drug: anti-HBc level
Normalized name: Aminosyn-HBC 7 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-HBc level ≥325 IU/ml
Study: 36152268
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-HBc <325 IU/ml with HBsAg >3008 IU/ml
Study: 36152268
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-HBc <325 IU/ml with HBcrAg ≥1790 U/ml
Study: 36258168
Drug: Padres Preparados,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Padres Preparados, Jóvenes Saludables program (8 weekly sessions of 2.5 hours each)
Study: 34019540
Drug: Usual medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medicine access (n = 391)
Study: 36129708
Drug: Nonpharmacologic interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonpharmacologic interventions including earplugs, eye mask, aromatherapy, and postponed morning medication and vital sign measurement rounds.
Study: 36129708
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group with postponed vital sign checks and medication rounds.
Study: 33177349
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) combo therapy
Study: 34018375
Drug: MRI after
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI after vaginal filling with ultrasound gel
Study: 32176792
Drug: Linezolid administered
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid administered intravenously at a standard dose of 600 mg every 12 hours with CVVH
Study: 32176792
Drug: Linezolid administered
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid administered intravenously at a standard dose of 600 mg every 12 hours with EDH
Study: 32176792
Drug: Standard 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 600 mg intravenous administration every 12 hours
Study: 33443915
Drug: Twice‐daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice‐daily application of a commercially available skin and body lotion to the arms and legs of participants
Study: 34062589
Drug: Team-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Team-based treatment (blended collaborative care) in secondary prevention
Study: 33744043
Drug: BUZZY® vibratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUZZY® vibratory stimulation tool (switched on before injection)
Study: 33264556
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no trial drug)
Study: 32950590
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg/day)
Study: 34343292
Drug: 60 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg/day of D3 for 8 weeks
Study: 34343292
Drug: 20 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg/day of 25(OH)D3 for 8 weeks
Study: 35331677
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (4 g of magnesium sulphate heptahydrate, 8 mmol magnesium ions)
Study: 33364042
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A plus E supplementation (AE group, N = 36)
Study: 33364042
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A plus E with zinc (AEZ group, N = 35)
Study: 33364042
Drug: No supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplements (control group, N = 27)
Study: 33544819
Drug: 30 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg/day valproic acid orally for 14 days
Study: 32859487
Drug: Bilateral pectointercostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral pectointercostal fascial block using ropivacaine injection 0.25%
Study: 34516497
Drug: Xianling Gubao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xianling Gubao capsule + glucosamine hydrochloride capsule simulation agent treatment
Study: 34516497
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride capsule + Xianling Gubao capsule simulation agent treatment
Study: 36570810
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.5 mg/kg)
Study: 32305653
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement with adjuvant antimicrobial photodynamic therapy (aPDT)
Study: 35241006
Drug: Blister packaged
Normalized name: Blister Armour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blister packaged IFA pills
Study: 35241006
Drug: Loose packaged
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose packaged IFA pills
Study: 34019802
Drug: TAK-426 2
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-426 2 μg
Study: 34019802
Drug: TAK-426 5
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-426 5 μg
Study: 34019802
Drug: TAK-426 10
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-426 10 μg
Study: 34019802
Drug: TAK-426 10
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-426 10 μg vs 2 μg
Study: 34019802
Drug: TAK-426 10
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-426 10 μg vs 5 μg
Study: 35811050
Drug: CBD-rich oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD-rich oil administered within the reconsolidation window
Study: 35811050
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil administered within the reconsolidation window
Study: 35811050
Drug: CBD-rich oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD-rich oil administered outside of the reconsolidation window
Study: 33934618
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion at 1.25 IU/hour
Study: 33934618
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion at 2.5 IU/hour
Study: 33934618
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion at 5.0 IU/hour
Study: 32109318
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid and hydroquinone 4% cream, sunscreen
Study: 32109318
Drug: Hydroquinone 4%
Normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroquinone 4% cream, sunscreen, and placebo capsules
Study: 34560922
Drug: Olfactory ensheathing
Normalized name: BOS TAURUS OLFACTORY BULB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory ensheathing cell therapy
Study: 36056874
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg orally once daily for two weeks
Study: 33272965
Drug: Ziltivekimab 2
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 2 mg
Study: 33272965
Drug: Ziltivekimab 6
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 6 mg
Study: 33272965
Drug: Ziltivekimab 20
Normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziltivekimab 20 mg
Study: 33309466
Drug: Breathing Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing Therapy
Study: 33942396
Drug: High-dose glucocorticoids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucocorticoids, antibiotics, and monoclonal anti-TNFα antibody
Study: 33942396
Drug: Anti-PD-1 antibodies
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 antibodies
Study: 34001373
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A)
Study: 35634479
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (Group L)
Study: 33196927
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention including psychoeducation on PND, coping skills, healthy mother/child interaction, and infant stimulation in addition to routine treatment.
Study: 33196927
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving treatment as usual.
Study: 35701334
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT), transdermal gel (Tostran, 2%), maximum daily dose of 40 mg for 12 months
Study: 34729060
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg for 12 weeks)
Study: 36372869
Drug: LDL-C level
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C level at 6 months after randomization set at a threshold of 70 mg/dl
Study: 36372869
Drug: LDL-C level
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C level below 70 mg/dl
Study: 32617061
Drug: Oral macrolide
Normalized name: Macrobid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral macrolide therapy
Study: 32617061
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (oral steroid + macrolide)
Study: 32617061
Drug: Control (Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Oral steroid group)
Study: 33975465
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (fluoropyrimidine and platinum-based agent)
Study: 33975465
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (fluoropyrimidine and platinum-based agent)
Study: 34463929
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (target serum level 3 mg/dl)
Study: 34463929
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo, target serum level 1.9 mg/dl)
Study: 34463929
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate and normal saline (placebo)
Study: 33343498
Drug: Sensorimotor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensorimotor therapy
Study: 32209071
Drug: Input quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Input quality (availability of trained providers, drugs, and supplies)
Study: 34649217
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day ALA
Study: 34649217
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day ALA
Study: 34473896
Drug: Biological xenograft
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological xenograft
Study: 36414304
Drug: Leucocyte-poor platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte-poor platelet-rich plasma (PRP) injection after joint aspiration
Study: 34559359
Drug: Ciprofol initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ciprofol initial infusion for 30 min followed by continuous maintenance infusion for 4 hours
Study: 34559359
Drug: Ciprofol bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol bolus dose followed by continuous maintenance infusion for 12 hours
Study: 36644351
Drug: SCO-792 500
Normalized name: SCO-Spondin Derived Peptide NX210
DrugBank: NX-210c (DB18209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCO-792 500 mg once daily (SCO-792 QD)
Study: 36644351
Drug: SCO-792 500
Normalized name: SCO-Spondin Derived Peptide NX210
DrugBank: NX-210c (DB18209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCO-792 500 mg 3 times daily (SCO-792 TID)
Study: 33222542
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (SIRT) with Y-90 resin microspheres
Study: 36494706
Drug: Cardiac shockwave
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac shockwave therapy (SWT) during CABG surgery
Study: 32473644
Drug: CABG surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: CABG surgery with sham treatment
Study: 32964809
Drug: PAI-indicated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAI-indicated treatment in STEPd study
Study: 32964809
Drug: PAI-indicated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAI-indicated treatment in FreqMech study
Study: 32964809
Drug: Cross-trial predictions
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-trial predictions for indicated treatment
Study: 32557665
Drug: Intravenous garetosmab
Normalized name: Garetosmab
DrugBank: Garetosmab (DB16379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous garetosmab 0.3, 1, 3, or 10 mg/kg
Study: 32557665
Drug: Intravenous garetosmab
Normalized name: Garetosmab
DrugBank: Garetosmab (DB16379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous garetosmab 10 mg/kg
Study: 36163755
Drug: Quizartinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quizartinib (40 mg/day from days 8-21, followed by 30-60 mg/day for up to 3 years)
Study: 34336162
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group using original images for diagnosis and treatment.
Study: 34373901
Drug: Postoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesic effect after electrode insertion
Study: 33676783
Drug: 9vHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vHPV vaccine (three-dose regimen: day 1, month 2, month 6)
Study: 32954673
Drug: Biological movements
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological movements
Study: 34134711
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum urate (100 µmol/L)
Study: 34134711
Drug: Median serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median serum urate (300 µmol/L)
Study: 32353974
Drug: Gymnema sylvestre
Normalized name: GYMNEMA SYLVESTRE LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gymnema sylvestre (GS) solution
Study: 33611742
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 50 mg/kg intravenously, followed by infusion at a rate of 10 mg/kg/h during surgery
Study: 32871238
Drug: Calcifediol treatment
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcifediol treatment (0.532 mg on admission, 0.266 mg on days 3 and 7, then weekly until discharge or ICU admission)
Study: 32871238
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy (hydroxychloroquine and azithromycin) without calcifediol
Study: 39218235
Drug: Calcifediol treatment
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcifediol treatment
Study: 32871238
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy without calcifediol
Study: 34211099
Drug: High-dose BTxA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BTxA (8 U)
Study: 34211099
Drug: Low-dose BTxA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose BTxA (4 U)
Study: 32880343
Drug: PZQ 40
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ 40 mg/kg
Study: 32880343
Drug: PZQ 60
Normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ 60 mg/kg
Study: 32171600
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of botulinum toxin A (BTX‐A) in the masticator muscles before surgery
Study: 34569413
Drug: Lubricant gel
Normalized name: Surgilube Lubricant Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubricant gel (5 ml of water-soluble lubricant gel during cervical dilatation of 4 cm until complete cervical dilatation)
Study: 35986409
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose intake
Study: 32473640
Drug: OM3-CA 2
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-CA 2 g
Study: 32473640
Drug: OM3-EE 4
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OM3-EE 4 g
Study: 33002427
Drug: Nebulised ALX‐0171
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised ALX‐0171 3 mg/kg
Study: 33002427
Drug: Nebulised ALX‐0171
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised ALX‐0171 6 mg/kg
Study: 33002427
Drug: Nebulised ALX‐0171
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised ALX‐0171 9 mg/kg
Study: 32221987
Drug: Brivaracetam at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam at individualized doses ≤200 mg/d
Study: 36432445
Drug: Concentrated beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated beetroot juice (140 mL)
Study: 36432445
Drug: Low-nitrate control
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-nitrate control supplement
Study: 34768404
Drug: Albumin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (1.5 g/kg at baseline and 1 g/kg on day 3)
Study: 35303460
Drug: Community-based programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based programme for corneal ulcer prevention involving training of female community health volunteers (FCHVs) to diagnose corneal abrasions and provide a 3-day course of ophthalmic antimicrobials.